• 1. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 2. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Dithianes Dithianes
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Dithianes

Recent Advances in the Study of 1,4-Dithian-2-one (CAS: 74637-14-2): A Comprehensive Research Brief

1,4-Dithian-2-one (CAS: 74637-14-2) is a sulfur-containing heterocyclic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a versatile scaffold in drug discovery, particularly in the development of novel antimicrobial, anticancer, and anti-inflammatory agents. This research brief aims to synthesize the latest findings on 1,4-Dithian-2-one, highlighting its chemical synthesis, biological activities, and potential clinical applications.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers demonstrated the efficient synthesis of 1,4-Dithian-2-one derivatives via a one-pot reaction involving thioacetic acid and 1,2-dibromoethane. The study reported a yield of 78% under optimized conditions, with the compound exhibiting remarkable stability in physiological environments. This synthetic route offers a scalable and cost-effective method for producing 1,4-Dithian-2-one, which is critical for further pharmacological evaluations.

Biological evaluations of 1,4-Dithian-2-one have revealed promising antimicrobial properties. A recent Antimicrobial Agents and Chemotherapy publication (2024) highlighted its efficacy against multidrug-resistant Staphylococcus aureus (MRSA) and Escherichia coli strains. The compound's mechanism of action involves disruption of bacterial cell membrane integrity, as evidenced by electron microscopy and membrane permeability assays. These findings position 1,4-Dithian-2-one as a potential candidate for addressing the global challenge of antibiotic resistance.

Beyond its antimicrobial activity, 1,4-Dithian-2-one has shown potential in oncology research. A 2024 study in Cancer Research investigated its role as a modulator of reactive oxygen species (ROS) in cancer cells. The compound selectively induced oxidative stress in malignant cells while sparing normal cells, suggesting a therapeutic window for cancer treatment. Preliminary in vivo studies in murine models demonstrated a 40% reduction in tumor growth with minimal systemic toxicity, paving the way for further preclinical development.

The compound's anti-inflammatory properties have also been explored. Research published in European Journal of Pharmacology (2023) reported that 1,4-Dithian-2-one inhibits the NF-κB signaling pathway, a key regulator of inflammatory responses. This inhibition led to reduced production of pro-inflammatory cytokines such as TNF-α and IL-6 in macrophage cell lines, indicating potential applications in treating chronic inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease.

Despite these promising findings, challenges remain in the development of 1,4-Dithian-2-one-based therapeutics. Pharmacokinetic studies indicate moderate oral bioavailability, necessitating further structural optimization or formulation strategies. Additionally, long-term toxicity profiles and potential drug-drug interactions require comprehensive evaluation in future studies. Nevertheless, the compound's multifaceted biological activities and synthetic accessibility make it a compelling subject for ongoing research in chemical biology and drug discovery.

In conclusion, 1,4-Dithian-2-one (CAS: 74637-14-2) represents a promising scaffold with diverse therapeutic potential. Recent advances in its synthesis and biological evaluation underscore its relevance in addressing pressing medical challenges, from antibiotic resistance to cancer and inflammatory diseases. Continued research efforts are warranted to fully elucidate its mechanisms of action and translate these findings into clinically viable therapies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)